$ACOG

Opaleye Management Inc. purchased $976K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 152,533 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $6.40 ($6.40–$6.50, $0.98M total) across 2 trades over 2026-06-25 to 2026-06-26.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jun 29, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase amount and share count; it can modestly influence sentiment but does not change fundamentals in the text.

02

Market read

Traders may treat the filing as a small bullish signal, but without accompanying financial or operational updates it is unlikely to drive a sustained repricing.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; however, the article still lacks context on prior trading cadence, total stake changes over time, and whether the buyer is acting for strategic reasons.

Relevance 6/10Novelty 6/10Timing: after-hours/filing date (2026-06-29) for the 6/25–6/26 purchase disclosure

Background

This is an SEC Form 4 insider transaction disclosure: Opaleye Management Inc. bought ACOG shares indirectly as a 10% owner.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (10% owner) filed a Form 4 showing an open-market purchase of 152,533 ACOG shares for ~$976.5K (6/25–6/26).

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

Form 4 purchases can support bullish sentiment, but the article provides no new operating/financial information and the transaction is modest relative to typical market-moving thresholds.

Market effects

No sector-level read-through; this is company-specific ownership activity only.

None indicated.

None indicated.

Counterpoint

The purchase may be routine (e.g., liquidity management, tax planning, or indirect holdings mechanics) and not a strong directional signal.

Key entities

  • Alpha Cognition Inc.

    The company whose shares were purchased; Form 4 lists issuer as Alpha Cognition Inc. (ACOG).

  • Opaleye Management Inc.

    Reporter of the Form 4; disclosed an indirect open-market purchase totaling ~$976.5K.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.